Tradename | Company | Number | Date | Products |
---|---|---|---|---|
GEMCITABINE HYDROCHLORIDE | Accord Healthcare | N-209604 RX | 2017-08-03 | 4 products, RLD, RS |
GEMCITABINE HYDROCHLORIDE | Hospira | N-200795 RX | 2011-08-04 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
gemcitabine | ANDA | 2025-02-03 |
gemcitabine gemcitabine | ANDA | 2019-09-12 |
gemcitabine hydrochloride | ANDA | 2025-01-09 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Gemcitabine Hydrochloride, Infugem, Sun Pharm | |||
9241948 | 2033-07-01 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Biliary tract neoplasms | D001661 | — | C24.9 | — | — | 1 | — | — | 1 |
Drug common name | Gemcitabine |
INN | gemcitabine |
Description | Gemcitabine is a 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It has a role as a photosensitizing agent, a DNA synthesis inhibitor, a prodrug, an EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor, an environmental contaminant, a xenobiotic, a radiosensitizing agent, an antineoplastic agent, an antimetabolite, an antiviral drug and an immunosuppressive agent. It is an organofluorine compound and a pyrimidine 2'-deoxyribonucleoside. |
Classification | Small molecule |
Drug class | nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1 |
PDB | — |
CAS-ID | 95058-81-4 |
RxCUI | — |
ChEMBL ID | CHEMBL888 |
ChEBI ID | 175901 |
PubChem CID | 60750 |
DrugBank | DB00441 |
UNII ID | B76N6SBZ8R (ChemIDplus, GSRS) |